Glycogen Phosphorylase Inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea Improves Glucose Tolerance Under Normoglycemic and Diabetic Conditions and Rearranges Hepatic Metabolism

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 13

PMID 23936011

Citations 13

Authors

Lilla Nagy

Tibor Docsa

Magdolna Szanto

Attila Brunyanszki

Csaba Hegedus

Judit Marton

Balint Konya

Laszlo Virag

Laszlo Somsak

Pal Gergely

Peter Bai

Affiliations

Soon will be listed here.

Abstract

Glycogen phosphorylase (GP) catalyzes the breakdown of glycogen and largely contributes to hepatic glucose production making GP inhibition an attractive target to modulate glucose levels in diabetes. Hereby we present the metabolic effects of a novel, potent, glucose-based GP inhibitor (KB228) tested in vitro and in vivo under normoglycemic and diabetic conditions. KB228 administration enhanced glucose sensitivity in chow-fed and obese, diabetic mice that was a result of higher hepatic glucose uptake. Besides improved glucose sensitivity, we have observed further unexpected metabolic rearrangements. KB228 administration increased oxygen consumption that was probably due to the overexpression of uncoupling protein-2 (UCP2) that was observed in animal and cellular models. Furthermore, KB228 treatment induced mammalian target of rapamycin complex 2 (mTORC2) in mice. Our data demonstrate that glucose based GP inhibitors are capable of reducing glucose levels in mice under normo and hyperglycemic conditions. Moreover, these GP inhibitors induce accommodation in addition to GP inhibition--such as enhanced mitochondrial oxidation and mTORC2 signaling--to cope with the glucose influx and increased glycogen deposition in the cells, however the molecular mechanism of accommodation is unexplored.

Citing Articles

The effect of hormones insulin and glucagon on ubiquitin modifications elucidated by proteomics in liver cells.

Vemana H, Dukhande V Life Sci. 2023; 329:121935.

PMID: 37442415 PMC: 10528490. DOI: 10.1016/j.lfs.2023.121935.

Bioinformatics and Next-Generation Data Analysis for Identification of Genes and Molecular Pathways Involved in Subjects with Diabetes and Obesity.

Ganekal P, Vastrad B, Kavatagimath S, Vastrad C, Kotrashetti S Medicina (Kaunas). 2023; 59(2).

PMID: 36837510 PMC: 9967176. DOI: 10.3390/medicina59020309.

Dual-Target Compounds against Type 2 : Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors.

Sipos A, Szennyes E, Hajnal N, Kun S, Szabo K, Uray K Pharmaceuticals (Basel). 2021; 14(4).

PMID: 33920838 PMC: 8071193. DOI: 10.3390/ph14040364.

Glycogen phosphorylase inhibitor, 2,3-bis[(2E)-3-(4-hydroxyphenyl)prop-2-enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells.

Nagy L, Beke F, Juhasz L, Kovacs T, Juhasz-Toth E, Docsa T PLoS One. 2020; 15(9):e0236081.

PMID: 32960890 PMC: 7508380. DOI: 10.1371/journal.pone.0236081.

Synthesis of New C- and N-β-d-Glucopyranosyl Derivatives of Imidazole, 1,2,3-Triazole and Tetrazole, and Their Evaluation as Inhibitors of Glycogen Phosphorylase.

Kun S, Bokor E, Sipos A, Docsa T, Somsak L Molecules. 2018; 23(3).

PMID: 29543771 PMC: 6017874. DOI: 10.3390/molecules23030666.

References

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

Osz E, Somsak L, Szilagyi L, Kovacs L, Docsa T, Toth B . Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin. Bioorg Med Chem Lett. 1999; 9(10):1385-90. DOI: 10.1016/s0960-894x(99)00192-4. View

Varga G, Docsa T, Gergely P, Juhasz L, Somsak L . Synthesis of tartaric acid analogues of FR258900 and their evaluation as glycogen phosphorylase inhibitors. Bioorg Med Chem Lett. 2013; 23(6):1789-92. DOI: 10.1016/j.bmcl.2013.01.042. View

Stalmans W, Bollen M, Toth B, Gergely P . Short-term hormonal control of protein phosphatases involved in hepatic glycogen metabolism. Adv Enzyme Regul. 1990; 30:305-27. DOI: 10.1016/0065-2571(90)90024-v. View

Oikonomakos N, Somsak L . Advances in glycogen phosphorylase inhibitor design. Curr Opin Investig Drugs. 2008; 9(4):379-95. View

Guertin D, Sabatini D . Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. DOI: 10.1016/j.ccr.2007.05.008. View

Horimoto M, Fulop P, Derdak Z, Wands J, Baffy G . Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology. 2004; 39(2):386-92. DOI: 10.1002/hep.20047. View

Brunyanszki A, Hegedus C, Szanto M, Erdelyi K, Kovacs K, Schreiber V . Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress. J Invest Dermatol. 2010; 130(11):2629-37. DOI: 10.1038/jid.2010.190. View

Adam-Vizi V, Chinopoulos C . Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci. 2006; 27(12):639-45. DOI: 10.1016/j.tips.2006.10.005. View

10.

Zhang T, Wang S, Lin Y, Xu W, Ye D, Xiong Y . Acetylation negatively regulates glycogen phosphorylase by recruiting protein phosphatase 1. Cell Metab. 2012; 15(1):75-87. PMC: 3285296. DOI: 10.1016/j.cmet.2011.12.005. View

11.

Somsak L, Felfoldi N, Konya B, Huse C, Telepo K, Bokor E . Assessment of synthetic methods for the preparation of N-beta-d-glucopyranosyl-N'-substituted ureas, -thioureas and related compounds. Carbohydr Res. 2008; 343(12):2083-93. DOI: 10.1016/j.carres.2008.01.045. View

12.

Lerin C, Montell E, Nolasco T, Garcia-Rocha M, Guinovart J, Gomez-Foix A . Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. Biochem J. 2003; 378(Pt 3):1073-7. PMC: 1224012. DOI: 10.1042/BJ20030971. View

13.

Favaro E, Bensaad K, Chong M, Tennant D, Ferguson D, Snell C . Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab. 2012; 16(6):751-64. DOI: 10.1016/j.cmet.2012.10.017. View

14.

Agius L . New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metab. 2007; 21(4):587-605. DOI: 10.1016/j.beem.2007.09.001. View

15.

Fulop P, Derdak Z, Sheets A, Sabo E, Berthiaume E, Resnick M . Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology. 2006; 44(3):592-601. DOI: 10.1002/hep.21310. View

16.

Kelsall I, Rosenzweig D, Cohen P . Disruption of the allosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance in vivo. Cell Signal. 2009; 21(7):1123-34. DOI: 10.1016/j.cellsig.2009.03.001. View

17.

Colombo S, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, Tudzarova S . Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc Natl Acad Sci U S A. 2011; 108(52):21069-74. PMC: 3248543. DOI: 10.1073/pnas.1117500108. View

18.

Nishikawa T, Edelstein D, Du X, Yamagishi S, Matsumura T, Kaneda Y . Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000; 404(6779):787-90. DOI: 10.1038/35008121. View

19.

Chrysina E, Kosmopoulou M, Tiraidis C, Kardakaris R, Bischler N, Leonidas D . Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1, 3, 4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. Protein Sci. 2005; 14(4):873-88. PMC: 2253430. DOI: 10.1110/ps.041216105. View

20.

Guertin D, Stevens D, Thoreen C, Burds A, Kalaany N, Moffat J . Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006; 11(6):859-71. DOI: 10.1016/j.devcel.2006.10.007. View